Quick Answer
Aptose Biosciences Inc. reported Cash and Equivalents of $935.0 thousand for fiscal year 2025.
Aptose Biosciences Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $935.0K | -84.8% |
| 2024 | $6.15M | -33.5% |
| 2023 | $9.25M | -75.0% |
| 2022 | $36.97M | -5.5% |
| 2021 | $39.11M | -66.7% |
| 2020 | $117.39M | +47.0% |
| 2019 | $79.84M | +421.9% |
| 2018 | $15.30M | +43.9% |
| 2017 | $10.63M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $613.0K | -92.3% | +10.8% |
| June 30, 2025 | $553.0K | -93.4% | -88.3% |
| March 31, 2025 | $4.74M | -35.4% | -22.9% |
| December 31, 2024 | $6.15M | -33.5% | -22.7% |
| September 30, 2024 | $7.96M | -49.4% | -4.4% |
| June 30, 2024 | $8.33M | -0.8% | +13.4% |
| March 31, 2024 | $7.35M | -67.7% | -20.6% |
| December 31, 2023 | $9.25M | -75.0% | -41.1% |
- Aptose Biosciences Inc. showed a decrease of -84.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, Aptose Biosciences Inc.’s cash and equivalents has declined by 91.2% (from $10.63 million to $935.0 thousand).
- The most recent figure is from Aptose Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: